An overlooked mental health challenge faced by new mothers. A powerful new drug could be critical in fighting back. It should have been an obvious match. Yet things may not turn out that way because of pharma industry’s pricing vagaries as well as the lack of conversation around the condition itself.
Related Posts
An army of 12,000 medical reps: How Rajeev Juneja flexed Mankind to the pharma top order
Synopsis While Ramesh Juneja has led Mankind Pharma for three decades, his brother Rajeev kept in tow and took charge…
syngene: Syngene gets booster dose of sky-high valuation, but investors cautiously upbeat on stock
Contract research and manufacturing company Syngene International has had a fabulous run this year. Its stock price has risen over…
Why Mankind, Dr Reddy’s and PE firms are so interested in low-profile BSV
Image credit: Compiled by Manali Ghosh via AI Synopsis Advent controlled-BSV has charted an exceptional turnaround over the last five…